{
    "title": "Biosimilar copies of blockbuster drug launch in major EU markets",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-2968201/Biosimilar-copies-blockbuster-drug-launch-major-EU-markets.html",
    "date": "2015-02-25",
    "keywords": [
        "drug",
        "remicade",
        "gmt",
        "hospira",
        "mundipharma",
        "johnson",
        "month",
        "remsima",
        "italy",
        "inflectra",
        "france",
        "launch",
        "eu",
        "email",
        "ben",
        "hirschlerlondon",
        "rheumatoid",
        "arthritis",
        "crohns",
        "disease",
        "advance",
        "type",
        "biosimilarsthe",
        "firm",
        "celltrion",
        "potential",
        "business",
        "factor",
        "decision",
        "wednesday",
        "biosimilar",
        "belgium",
        "luxembourg",
        "expiry",
        "patentshospira",
        "product",
        "denmark",
        "germany",
        "greece",
        "sale",
        "move",
        "step",
        "biotechnology",
        "industrybecause",
        "biotech",
        "notion",
        "jobremicade",
        "antibody",
        "infliximabthere",
        "debate",
        "takeup",
        "britain",
        "testmany",
        "cancer",
        "eye",
        "development",
        "threat",
        "roche",
        "analyst",
        "value",
        "innovator",
        "upside",
        "society",
        "jahnsen",
        "professor",
        "medicine",
        "gastroenterology",
        "university",
        "oslo",
        "use",
        "infliximab",
        "healthcare",
        "system",
        "test",
        "food",
        "administration",
        "committee",
        "march",
        "version",
        "goodman"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}